Organization
Stanford Cancer Center
19 abstracts
Abstract
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.Org: Sun Yat-sen University Cancer Centre, Collaborative Innovation Centre for Cancer Medicine, Hunan Cancer Hospital, Department of Radiation Oncology, Affiliated Hospital of Guizhou Medical University,
Abstract
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein–Barr virus-associated nasopharyngeal carcinoma.Org: Stanford Cancer Center, University of Pennsylvania, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,
Abstract
Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy.Org: Stanford Cancer Institute, Stanford Cancer Center,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.Org: Northwestern University Feinberg School of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Regional and Virgen de la Victoria University Hospitals, IBIMA, Hospital Clínic de Barcelona, IDIBAPS,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.Org: Moffitt Cancer Center, Stanford Cancer Center, Washington University School of Medicine in St Louis, University of Washington and Fred Hutchinson Cancer Research Centre, Massachusetts General Hospital,
Abstract
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.Org: Stanford Cancer Center, Portuguese Oncology Institute of Porto, Porto, Portugal, The Kinghorn Cancer Centre, CUF Instituto de Oncologia, Macquarie University,
Abstract
Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis.Org: Natera, Inc., Stanford University Medical Center, Stanford, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Rush University Medical Center, Stanford Cancer Center,
Abstract
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).Org: University of Pennsylvania, Stanford Cancer Center,
Abstract
Plasma cell leukemia: A multicenter retrospective study of 150 patients.Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Department of Internal Medicine, University of Utah, Fred Hutchinson Cancer Research Center,
Abstract
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).Org: Memorial Sloan Kettering Cancer Center, University of Wisconsin, Madison, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, University of California Irvine, Sarah Cannon and HCA Research Institute,
Abstract
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California Irvine, MD Anderson Hematology/Oncology Fellowship, The Medical College of Wisconsin,
Abstract
Phase I/IIa clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein Barr virus positive nasopharyngeal cancer with pharmacokinetic and pharmacodynamic correlative studies.Org: Stanford Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Institut Gustave Roussy, The University of Hong Kong, University of Texas at MD Anderson Cancer Center,
Abstract
Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials: Two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis.Org: Stanford Cancer Center, University of Pavia, IQVIA, Amsterdam, Netherlands, Alexion Pharmaceuticals, AstraZeneca Rare Disease,
Abstract
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.Org: Washington University School of Medicine in St Louis, Stanford Cancer Center, Centre Léon Bérard, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.Org: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Princess Margaret Cancer Centre,
Abstract
Opioid prescribing patterns for head and neck cancer radiation patients, with a comparison to breast cancer radiation patients.Org: Stanford Cancer Center, Stanford Cancer Institute,